These findings suggested that KO EP300 or CREBBP promoted differentiation and potentially reduced proliferation in MLL-r AML cells but not MLL wild-type cells (Fig. 2F and additional file 1: Fig. S2C). Here, CREBBP is linked to acute myeloid leukemia.